Sera Prognostics (NASDAQ:SERA) CFO Austin Aerts Sells 5,232 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,232 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total value of $15,905.28. Following the completion of the sale, the chief financial officer directly owned 273,087 shares in the company, valued at approximately $830,184.48. This represents a 1.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Austin Aerts also recently made the following trade(s):

• On Thursday, September 11th, Austin Aerts sold 915 shares of Sera Prognostics stock. The stock was sold at an average price of $3.13, for a total value of $2,863.95.

Sera Prognostics Price Performance

Shares of SERA stock traded down $0.17 on Thursday, hitting $3.23. 4,627 shares of the company’s stock were exchanged, compared to its average volume of 168,836. The company has a 50 day moving average of $3.18 and a 200 day moving average of $2.79. The stock has a market cap of $124.66 million, a P/E ratio of -4.19 and a beta of 0.97. Sera Prognostics, Inc. has a 12 month low of $1.37 and a 12 month high of $9.13.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.10 million. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%. Sell-side analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors have recently added to or reduced their stakes in SERA. XTX Topco Ltd bought a new position in shares of Sera Prognostics during the first quarter valued at $39,000. Nuveen LLC acquired a new stake in Sera Prognostics in the first quarter valued at $138,000. Aberdeen Group plc bought a new position in Sera Prognostics during the 1st quarter worth $4,563,000. Ghisallo Capital Management LLC acquired a new position in Sera Prognostics during the 1st quarter worth about $368,000. Finally, Baker BROS. Advisors LP grew its position in shares of Sera Prognostics by 1.2% in the 1st quarter. Baker BROS. Advisors LP now owns 5,498,170 shares of the company’s stock valued at $20,233,000 after buying an additional 63,771 shares during the last quarter. 54.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on SERA shares. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.